KNSA stock forecast, quote, news & analysis
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases... Show more
Why Kiniksa Pharmaceuticals (KNSA) Stock Is Up +16% in the Last 30 Days
Key Takeaways
- KNSA shares climbed roughly 16% over the last 30 days, a move driven primarily by a strong third-quarter 2026 earnings report and accelerating ARCALYST demand.
- ARCALYST net product revenue reached $286.0 million in Q3 2026, up about 58% year over year from $180.9 million in the prior-year quarter.
- Management raised its full-year 2026 ARCALYST revenue guidance to between $1.045 billion and $1.050 billion, putting the therapy on a blockbuster trajectory.
- Over the last quarter the stock advanced more than 35% from the mid-$60s, extending a broader multi-month uptrend supported by revenue growth and pipeline progress.
- Forward catalysts include Phase 3 data for KPL-387, initiation of a Phase 1 trial for KPL-1161, and the continued launch trajectory of ARCALYST.
- For additional detail on valuation and expectations, explore Kiniksa's Price Targets, Earnings, and Forecast pages.
- For data-driven trading ideas across the market, explore Trending AI Robots.
Kiniksa Pharmaceuticals (KNSA) Company Overview and Market Position
Kiniksa Pharmaceuticals International, plc is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for cardiovascular and autoimmune diseases with significant unmet need. Its lead product, ARCALYST (rilonacept), is an interleukin-1 alpha and beta cytokine trap and the first FDA-approved therapy for recurrent pericarditis, a chronic autoinflammatory cardiovascular condition. ARCALYST also holds approvals for cryopyrin-associated periodic syndromes (CAPS) and deficiency of IL-1 receptor antagonist (DIRA).
The company's pipeline is anchored by KPL-387, an investigational, fully human IgG2 monoclonal antibody designed to enable once-monthly subcutaneous dosing for recurrent pericarditis, and KPL-1161, an Fc-modified antibody targeting quarterly dosing. Investors follow KNSA closely because ARCALYST enjoys a first-mover position in an underserved market, supported by orphan drug exclusivity and a direct-to-consumer marketing push aimed at expanding patient awareness and demand.
Kiniksa Pharmaceuticals (KNSA) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, KNSA shares rose approximately 16%, moving from a closing price near $75 in late September to an intraday level above $87 in late October. The advance was concentrated around the company's third-quarter earnings release, with the shares gapping higher as investors absorbed stronger-than-expected ARCALYST revenue and raised full-year guidance.
Over the last quarter, the move is even more pronounced. From a closing price in the mid-$60s in late July, the stock has climbed more than 35%, punctuated by a sharp rally following second-quarter results in late July and a further leg higher on the October third-quarter report. The broader trend reflects sustained revenue acceleration rather than a single isolated event, though near-term trading remains sensitive to earnings prints and pipeline updates.
What Drove KNSA Stock Price in the Last 30 Days
The dominant catalyst for the 30-day move was Kiniksa's third-quarter 2026 earnings report. ARCALYST net product revenue reached $286.0 million, a roughly 58% year-over-year increase from $180.9 million, underscoring continued adoption in recurrent pericarditis. Management also tightened its full-year outlook, guiding ARCALYST net product revenue to between $1.045 billion and $1.050 billion for 2026, a threshold consistent with blockbuster status.
Beyond the headline results, investor sentiment was supported by the company's pipeline narrative. Kiniksa reiterated its expectation for pivotal Phase 3 data from the PASTORALE trial of KPL-387 in the second half of 2027, with potential commercialization in 2028 or 2029, and reaffirmed plans to initiate a Phase 1 trial for KPL-1161 by the end of 2026. Rising volumes on earnings days indicate heightened institutional and retail participation, and the stock's premium valuation suggests the market is pricing in continued execution on both the commercial and clinical fronts.
What Drove KNSA Stock Performance Over the Last Quarter
The quarterly advance reflects a larger narrative of accelerating revenue and improving profitability. The late-July second-quarter report triggered a pronounced single-day surge, as ARCALYST posted record quarterly revenue and the company raised full-year guidance, reinforcing the therapy's growth runway in a market it currently leads.
Throughout the quarter, the stock consolidated in the mid-$70s to low-$80s range before breaking higher again on the October third-quarter results. Pipeline milestones, including FDA Orphan Drug Designation for KPL-387 and progress toward a first-in-human trial for KPL-1161, added to the long-term growth story. This combination of commercial momentum, expanding guidance, and a maturing pipeline drove the multi-month uptrend, even as the shares traded at a valuation premium relative to broader biotech peers.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of AI-driven trading bots from a broader universe of hundreds of bots that monitor thousands of tickers. Only the top-performing and most relevant bots appear in this section, each varying by strategy, timeframe, and performance metrics to suit different trading styles and risk profiles. The page is designed to help traders and investors discover data-driven approaches without requiring manual chart analysis. For those seeking automated, signal-based insights across the market, exploring the Trending AI Robots section can be a practical starting point.
KNSA Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the primary variable for KNSA is the continued launch trajectory of ARCALYST and whether it sustains the growth implied by the company's blockbuster revenue guidance. Quarterly ARCALYST revenue, patient and prescriber adoption, and any commentary on the direct-to-consumer campaign's effectiveness will be closely watched.
On the pipeline side, investors will monitor enrollment and execution in the pivotal Phase 3 PASTORALE trial of KPL-387, with data expected in the second half of 2027, as well as the planned initiation of a Phase 1 study for KPL-1161 by the end of 2026. Competitive dynamics in recurrent pericarditis, potential regulatory developments, and broader biotech sentiment and interest-rate conditions also represent meaningful factors. Given the stock's premium valuation, execution on guidance and clinical timelines will remain central to the investment narrative.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
KNSA's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for KNSA turned positive on October 27, 2026. Looking at past instances where KNSA's MACD turned positive, the stock continued to rise in 38 of 42 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on KNSA as a result. In 81 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
KNSA moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for KNSA crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +9.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where KNSA advanced for three days, in 231 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The 10-day RSI Indicator for KNSA moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 47 similar instances where the indicator moved out of overbought territory. In 34 of the 47 cases, the stock moved lower in the following days. This puts the odds of a move lower at 72%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KNSA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
KNSA broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for KNSA entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 1 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. KNSA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 40 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.127) is normal, around the industry mean (8.179). P/E Ratio (88.009) is within average values for comparable stocks, (-0.806). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.046) among similar stocks. P/S Ratio (7.564) is also within normal values, averaging (181.047).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsGeneric